Cell therapy in Parkinson's disease — stop or go?

Nature Reviews Neuroscience

Volumn 2, Issue 5, 2001, Pages 365-369

  Dunnett, Stephen B ^a   Björklund, Anders ^b   Lindvall, Olle ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BRAIN TRANSPLANTATION; CLINICAL TRIAL; EDITORIAL; HUMAN; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; STATISTICS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ANIMALS; BRAIN TISSUE TRANSPLANTATION; CLINICAL TRIALS; HUMANS; PARKINSON DISEASE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0035347165     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/35072572     Document Type: Article

References (57)

1. Freed, C. R. et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344, 710-719 (2001).
2. Kolata, G. Parkinson's disease is set back by failure of fet al cell implants. NY Times 8 March, 381 (2001).
3. Editorial. Prospects for Parkinson's disease. Nature Med. 7, 381 (2001).
4. 3H-noradrenaline uptake studies using tissue transplantation to the anterior chamber of the eye. Acta Physiol. Scand. 348, S1-S112 (1970).
5. Olson, L. & Seiger, A. Brain tissue transplanted to the anterior chamber of the eye. I. Fluorescence histochemistry of immature catecholamine and 5-hydroxytryptamine neurons innervating the iris. Z. Zellforsch. 195, 175-194 (1972).
6. Olson, L., Seiger, A. & Stromberg, I. Intraocular transplantation in rodents: a detailed account of the procedure and examples of its use in neurobiology with special reference to brain tissue grafting. Adv. Cell. Neurobiol. 4, 407-442 (1983).
7. Stenevi, U., Bjorklund, A. & Svendgaard, N.-A. Transplantation of central and peripheral monoamine neurons to the adult rat brain: techniques and conditions for survival. Brain Res. 114, 1-20 (1976).
8. Bjorklund, A., Schmidt, R. H. & Stenevi, U. Functional reinnervation of the neostriatum in the adult rat by use of intraparenchymal grafting of dissociated cell suspensions from the substantia nigra. Cell Tissue Res. 212, 39-45 (1980).
9. Perlow, M. J. et al. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204, 643-647 (1979).
10. Bjorklund, A. & Stenevi, U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral transplants. Brain Res. 177, 555-560 (1979).
11. Bjorklund, A., Dunnett, S. B., Stenevi, U., Lewis, M. E. & Iversen, S. D. Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res. 199, 307-333 (1980).
12. Dunnett, S. B., Bjorklund, A., Schmidt, R. H., Stenevi, U. & Iversen, S. D. Intracerebral grafting of neuronal cell suspensions. V. Behavioral recovery in rats with bilateral 6-OHDA lesions following implantation of nigral cell suspensions. Acta Physiol. Scand. 522, S39-S47 (1983).
13. Schmidt, R. H., Bjorklund, A., Stenevi, U., Dunnett, S. B. & Gage, F. H. Intracerebral grafting of neuronal cell suspensions. III. Activity of intrastriatal nigral suspension implants as assessed by measurements of dopamine synthesis and metabolism. Acta Physiol. Scand. 522, S19-S28 (1983).
14. Sauer, H. & Brundin, P. Effects of cool storage on survival and function of intrastriatal ventral mesencephalic grafts. Rest. Neurol. Neurosci. 2, 123-135 (1991).
15. Nikkhah, G. et al. A microtransplantation approach for cell suspension grafting in the rat Parkinson model: A detailed account of the methodology. Neuroscience 63, 57-72 (1994).
16. Brundin, P. et al. Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant. 9, 179-195 (2000).
17. Winkler, C., Kirik, D., Bjorklund, A. & Dunnett, S. B. Transplantation in the rat model of Parkinson's disease: ectopic versus homotopic graft placement. Prog. Brain Res. 127, 233-265 (2000).
18. Taylor, J. R. et al. Grafting of fet al substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls. Exp. Brain Res. 85, 335-348 (1991).
19. Annett, L. E., Torres, E. M., Ridley, R. M., Baker, H. F. & Dunnett, S. B. A comparison of the behavioural effects of embryonic nigral grafts in the caudate nucleus and in the putamen of marmosets with unilateral 6-OHDA lesions. Exp. Brain Res. 103, 355-371 (1995).
20. Dunnett, S. B. & Bjorklund, A. in Functional Neural Transplantation (eds Dunnett, S. B. & Bjorklund, P.) 531-567 (Raven, New York, 1994).
21. Backlund, E. O. et al. Transplantation of adrenal medullary tissue to striatum in parkinsonism. J. Neurosurg. 62, 169-173 (1985).
22. Madrazo, I. et al. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N. Engl. J. Med. 316, 831-834 (1987).
23. Quinn, N. P. The clinical application of cell grafting techniques in patients with Parkinson's disease. Prog. Brain Res. 82, 619-625 (1990).
24. Boer, G. J. Ethical guidelines for the use of human embryonic or fet al tissue for experimental and clinical neurotransplantation and research. J. Neurol. 242, 1-13 (1994).
25. Madrazo, I. et al. Transplantation of fet al substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. N. Engl. J. Med. 318, 51 (1988).
26. Lindvall, O. et al. Human fet al dopamine neurons grafted into the striatum in 2 patients with severe Parkinson's disease: a detailed account of methodology and a 6-month follow-up. Arch. Neurol. 46, 615-631 (1989).
27. Langston, J. W., Widner, H. & Goetz, C. G. Core assessment program for intracerebral transplantation (CAPIT). Mov. Disord. 7, 2-13 (1992).
28. Defer, G. L., Widner, H., Marie, R. M., Remy, P. & Levivier, M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT- PD). Mov. Disord. 14, 572-584 (1999).
29. Lindvall, O. & Hagell, P. Clinical observations after neural transplantation in Parkinson's disease. Prog. Brain Res. 127, 299-320 (2000).
30. Lindvall, O. et al. Grafts of fet al dopamine neurons survive and improve motor function in Parkinson's disease. Science 247, 574-577 (1990).
31. Lindvall, O. et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann. Neurol. 35, 172-180 (1994).
32. Wenning, G. K. et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann. Neurol. 42, 95-107 (1997).
33. Hagell, P. et al. Sequential bilateral transplantation in Parkinson's disease — effects of the second graft. Brain 122, 1121-1132 (1999).
34. Brundin, P. et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123, 1380-1390 (2000).
35. Widner, H. et al. Bilateral fet al mesencephalic grafting in 2 patients with parkinsonism induced by 1-methyl-4- phenyl-1, 2, 3, 6- tetrahydropyridine (MPTP). N. Engl. J. Med. 327, 1556-1563 (1992).
36. Sawle, G. V. et al. Transplantation of fet al dopamine neurons in Parkinson's disease: PET [F-18] 6-l- fluorodopa studies in 2 patients with putaminal implants. Ann. Neurol. 31, 166-173 (1992).
37. Piccini, P. et al. Dopamine release from nigral transplants visualised in vivo in a Parkinson's patient. Nature Neurosci. 2, 1137-1140 (1999).
38. Brundin, P. in Neural Transplantation: A Practical Approach Transplantation (eds Dunnett, S. B. & Bjorklund, P) 139-160 (IRL, Oxford, 1992).
39. Freeman, T. B. et al. Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N. Engl. J. Med. 341, 988-992 (1999).
40. Macklin, R. Placebo surgery in trials of therapy for Parkinson's disease. Reply. N. Enql. J. Med. 342, 355 (2000).
41. Widner, H. et al. NIH neural transplantation funding. Science 263, 737 (1994).
42. Kordower, J. H. et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fet al mesencephalic tissue in a patient with Parkinson's disease. N. Enql. J. Med. 332, 1118-1124 (1995).
43. Lee, C. S., Cenci, M. A., Schulzer, M. & Bjorklund, A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 123, 1365-1379 (2000).
44. Dunnett, S. B. & Bjorklund, A. Parkinson's disease: prospects for novel restorative and neuroprotective treatments. Nature 399, S32-S39 (1999).
45. Dunnett, S. B. et al. in NeurochemistryTransplantation (eds Teelken, A. W. & Korf, J.) 249-257 (Plenum, New York, 1997).
46. Deacon, T. et al. Histological evidence of fet al pig neural cell survival after transplantation into a patient with Parkinson's disease. Nature Med. 3, 350-353 (1997).
47. Schumacher, J. M. et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 54, 1042-1050 (2000).
48. Piccini, P. et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann. Neurol. 48, 689-695 (2000).
49. Hauser, R. A. et al. Long-term evaluation of bilateral fet al nigral transplantation in Parkinson disease. Arch. Neurol. 56, 179-187 (1999).
50. Nguyen, J. P. et al. Bilateral intrastriatal grafts of fet al mesencephalic neurons in Parkinson's disease: long-term results in 9 patients. Mov. Disord. 15, S53-S54 (2000).
51. Mendez, I. et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fet al nigral tissue to glial cell line- derived neurotrophic factor in patients with Parkinson's disease — report of two cases and technical considerations. J. Neurosurq. 92, 863-869 (2000).
52. Defer, G. L. et al. Long-term outcome of unilaterally transplanted Parkinsonian patients. 1. Clinical approach. Brain 119, 41-50 (1996).
53. 18F]fluorodopa uptake in five grafted Parkinsonian patients. Ann. Neurol. 38, 580-588 (1995).
54. Dunnett, S. B., Bjorklund, A., Stenevi, U. & Iversen, S. D. Behavioral recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. 2. Bilateral lesions. Brain Res. 229, 457-470 (1981).
55. Dunnett, S. B., Bjorklund, A., Stenevi, U. & Iversen, S. D. Grafts of embryonic substantia nigra reinnervating the ventrolateral striatum ameliorate sensorimotor impairments and akinesia in rats with 6-OHDA lesions of the nigrostriatal pathway. Brain Res. 229, 209-217 (1981).
56. Dunnett, S. B., Bjorklund, A., Stenevi, U. & Iversen, S. D. Behavioral recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. 1. Unilateral lesions. Brain Res. 215, 147-161 (1981).
57. Lindvall, O. et al. Fet al dopamine-rich mesencephalic grafts in Parkinson's disease. Lancet 2, 1483-1484 (1988)